“Many of the large [pharmaceutical] companies with active natural products programmes and associated bioprospecting efforts overseas have closed their programmes Today natural product discovery is found largely in smaller discovery companies, semi-governmental or governmental entities and universities around the world."
LAIRD, WYNBERG, Bioscience at a Crossroads: Implementing the Nagoya Protocol on Access and Benefit Sharing in a Time of Scientific, Technological and Industry Change, published by the CBD, 2012.
The Convention on Biological Diversity was inspired by the world community's growing commitment to sustainable development. The CBD was opened for signature in June 1992 and entered into force in December 1993. The Convention has 3 objectives:
The CBD obliges its members to facilitate access to their genetic resources (GR) and users of such resources to share in a fair and equitable way the results of research and development and the benefits arising from the commercial use of such resources.
The Nagoya Protocol is a supplementary agreement to the Convention on Biological Diversity (CBD), providing an international and transparent legal framework for the effective implementation of the third objective of the CBD. It was signed in October 2010, obliging signatories to take measures to ensure that only legally acquired genetic resources and associated traditional knowledge were utilized within their jurisdiction.
The Nagoya Protocol is expected to enter into force in 2014. Once operational, the Nagoya Protocol will generate significant benefits for biodiversity conservation in States that make the genetic resources over which they hold sovereign rights available. The Protocol rests on three main pillars:
Genetic resources – the gene pool in both natural and cultivated stocks – can play a significant role in many economic sectors. A broad range of players in the Union, including academic researchers and companies from different sectors of industry use genetic resources for research and development purposes.
Actors at the beginning of the genetic resources value chain in the Union (mostly collections and academic researchers) are in direct contact with the laws and authorities of provider countries. These first actors pass on samples of genetic resources and first research results to other users that engage in basic or applied research. Actors situated at the end of the genetic resource value change engage in often lengthy development activities that require significant investments with uncertain outcomes. They largely depend on material and information passed on to them from earlier users in the chain, including in relation to Access and Benefit Sharing agreements.
A clear framework of obligations for all users of genetic resources throughout the value chain is essential for creating an enabling context for facilitated access to quality samples of genetic resources with high legal certainty.
The European Union and all of its 27 Member States are Parties to the CBD. The Union and most of its Member States have signed the Nagoya Protocol and thereby committed themselves to work towards implementation and ratification. Union implementation and ratification of the Protocol will create new opportunities for nature-based research, and contribute to the development of a bio-based economy. To that purpose, the Commission recently made a proposal for a Regulation of the European Parliament and of the Council on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union.
Its objectives are to protect the rights of countries and of indigenous and local communities that allow their genetic resources and associated traditional knowledge to be used, while also giving researchers in Europe improved, simple and reliable access to quality samples of genetic resources.
EFPIA and IFPMA fully support the goals of the Convention on Biological Diversity (CBD) and stand ready to work with the EU to ensure the Protocol’s fair and balanced implementation across the EU.
Genetic material refers to any material of plant, animal, microbial or other origin containing functional units of heredity. Genetic resources refer to genetic material of actual or potential value.